Latest news about Mahamaya Lifesciences
Mahamaya Lifesciences
179.00
+3.15(+1.79%)
Company Performance:
View Company Insights1D+1.79%
1M-5.52%
6M+24.31%
1Y+54.31%
5Y+54.31%
More news about Mahamaya Lifesciences
26May 26
Mahamaya FY26 PAT rises 29% to ₹1,652 lakh on 25% revenue growth
Mahamaya Lifesciences Limited announced its audited financial results for FY26, reporting a 24.5% increase in revenue from operations to ₹32,887.30 lakh and a 28.97% rise in PAT to ₹1,652.33 lakh. EBITDA grew 32.06% to ₹3,425.88 lakh, with margins expanding to 10.42%, despite impacts from forex losses and listing expenses. The company remains focused on expanding its bio-based crop care portfolio and strengthening its market presence.
15Apr 26
Mahamaya Lifesciences Limited Exempt from Corporate Governance Compliance Due to BSE SME Listing
Mahamaya Lifesciences Limited has notified BSE Limited about its exemption from corporate governance compliance requirements under SEBI regulations. The company's listing on the BSE SME platform qualifies it for exemption under Regulation 15(2)(b), relieving it from filing quarterly, half-yearly, and yearly corporate governance reports as required under Regulation 27(2) of SEBI (LODR) Regulations, 2015.
04Apr 26
Mahamaya Lifesciences Files Quarterly Compliance Certificate for Q4FY26 Under SEBI Regulations
Mahamaya Lifesciences Limited submitted its Q4FY26 compliance certificate under SEBI Regulation 74(5) to BSE on April 4, 2026. KFin Technologies Limited, the company's registrar, confirmed the regulation is not applicable as all shares remain in demat form with no rematerialization requests received during the quarter ended March 31, 2026. Company Secretary Shilpi Bhardwaj signed the submission, demonstrating continued regulatory compliance.
03Apr 26
Mahamaya Lifesciences Confirms No Share Encumbrance by Promoters in FY26
Mahamaya Lifesciences Limited has filed its annual SEBI disclosure for FY26, confirming no encumbrance on promoter shares. Company Secretary Shilpi Bharadwaj submitted the filing on 3rd April 2026, while Managing Director Krishnamurthy Ganesan provided promoter group confirmation. The disclosure ensures compliance with SEBI Regulation 31(4) regarding substantial acquisition of shares and takeovers.
10Mar 26
Mahamaya Lifesciences Extends IPO Proceeds Utilisation Timeline to March 2028
Mahamaya Lifesciences Limited has extended its IPO proceeds utilisation timeline to March 2028, with Rs. 3449.03 lakhs remaining unutilised from total net proceeds of Rs. 6196.43 lakhs. The board-approved extension addresses technical execution factors for manufacturing plant implementation, including engineering cycles and equipment procurement timelines. The company confirmed no changes to project scope or objects of issue as disclosed in its November 2025 prospectus.
09Mar 26
Mahamaya Lifesciences Withdraws from Arihant Capital Virtual Conference Due to Scheduling Constraints
Mahamaya Lifesciences Limited has withdrawn from the Arihant Capital Bharat Connect Virtual Conference Rising Star 2026 scheduled for March 9, 2026, due to internal scheduling constraints and business priorities. The company communicated this decision to the Bombay Stock Exchange under SEBI regulations, reversing its earlier commitment made on March 5, 2026. Managing Director Krishnamurthy Ganesan signed the official withdrawal notification to maintain regulatory compliance and transparency with stakeholders.
22Jan 26
Mahamaya Lifesciences Limited Receives 'Company of the Year – Medium Scale' Award at ICSCE 2026, Dubai
Mahamaya Lifesciences Limited received the 'Company of the Year – Medium Scale' award at ICSCE 2026 in Dubai on January 20, 2026, presented by PMFAI. The company disclosed this achievement under SEBI Regulation 30 on January 22, 2026, highlighting its excellence in the pharmaceutical sector and compliance with regulatory requirements.
17Dec 25
Vijay Kedia Acquires 8.91 Lakh Shares in Mahamaya Lifesciences at ₹140 Per Share
Investor Vijay Kedia has purchased 8.91 lakh shares of Mahamaya Lifesciences, an SME-listed agro chemicals company, at ₹140 per share. The total investment amounts to ₹12.47 crores, representing a substantial stake in the small-cap firm. This move has drawn attention to the company and the agro chemicals sector.
02Dec 25
Mahamaya Lifesciences Reports 17.6% Profit Growth in H1 FY26
Mahamaya Lifesciences, a provider of agricultural crop protection solutions, announced unaudited financial results for H1 FY26. Revenue from operations increased by 11.5% to ₹16,306.37 lakhs. Standalone profit rose by 17.6% to ₹852.56 lakhs. Earnings per share improved by 7.1% to ₹4.80. The results were approved by the Board of Directors on December 02, 2025. The company's performance indicates strong market position and increasing demand for its products in the agricultural sector.
Industry Peers
UPL
PI Industries
Sumitomo Chemical
Bayer Crop Science
Sharda Cropchem
Dhanuka Agritech
Rallis
NACL Industries
Bhagiradha Chemicals & Industries
GSP Crop Science
580.00
(+4.55%)
2,366.80
(+2.59%)
460.85
(+1.19%)
3,779.50
(-2.93%)
743.10
(+0.19%)
973.30
(-0.91%)
203.80
(-0.17%)
146.75
(-1.43%)
246.85
(-0.44%)
482.10
(-0.40%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
